Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 37611128

Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Aug 24
First author
Palmer AC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304.
    note
    Source null
    related pmid
    34904799
    relationship
    Comment on

Authors and identifiers

  1. name
    Palmer AC
    type
    Author
  2. name
    Kurtz DM
    type
    Author
  3. name
    Alizadeh AA
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Palmer AC
    type
    Author
  2. name
    Kurtz DM
    type
    Author
  3. name
    Alizadeh AA
    type
    Author
bibliography ids
  1. nci-bib-4e22aaba214b099a83ee81a7
book metadata
content sha256
7e20961e1ddd0cf13676b81b620eea0f8632405c1dfce583c57f5a418e1629e8
document type
citation
dois
  1. 10.1056/NEJMc2306105
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:37611128
immutable id
pubmed:37611128@7e20961e1ddd0cf13676b81b620eea0f8632405c1dfce583c57f5a418e1629e8
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
8
name
The New England journal of medicine
nlm unique id
0255562
pages
764-766
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304.
    note
    Source null
    related pmid
    34904799
    relationship
    Comment on
outcomes validated
false
pmid
37611128
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
d63f2b2bb9de24f360b1c2b109630f04285c70f85e261b561ac717297f29e895
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Aug 24
precision
day
year
2023
publication types
  1. Letter
  2. Research Support, N.I.H., Extramural
  3. Comment
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37611128/
title
Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.

Preserved source evidence · Independent clinical review pending · Not medical advice